Abstract
Samples can be prone to ascertainment and attrition biases.The Australian Genetics of Depression Study is a large publicly recruited cohort (n=20,689) established to increase the understanding of depression and antidepressant treatment response. As part of the recruitment, participants donated a saliva sample and were given the option to consent to linkage of prescription records for research purposes. This study investigates differences between participants who donated a saliva sample or agreed to linkage of their records compared to those who did not. We observed that older, male participants with a higher education were more likely to donate a saliva sample. Self-reported bipolar disorder, ADHD, panic disorder, PTSD, substance use disorder and social anxiety disorder were associated with lower odds of donating a saliva sample whereas anorexia was associated with higher odds of donation. Male and younger participants showed higher odds of agreeing to record linkage. Participants with higher neuroticism scores and those with a history of bipolar disorder were also more likely to agree to record linkage whereas participants with a diagnosis of anorexia were less likely to agree. Increased likelihood of consent was also associated with increased genetic susceptibility to anorexia and reduced genetic risk for depression, and schizophrenia whereas there was no significant genetic effect for neuroticism. Overall, our results show moderate differences among these subsamples. Most current epidemiological studies do not adjust, nor search, for attrition biases at the genetic level. The possibility to do so is a strength of samples such as the AGDS. Our results suggest that analyses can be made more robust by identifying attrition biases both on the phenotypic and genetic level, and either contextualising them as a potential limitation or performing sensitivity analyses adjusting for them.
Competing Interest Statement
Professor Ian Hickie was a Commissioner in Australia's National Mental Health Commission from 2012-2018. He is the Co-Director, Health and Policy at the Brain and Mind Centre (BMC) University of Sydney. The BMC operates an early-intervention youth services at Camperdown under contract to headspace. Professor Hickie has previously led community-based and pharmaceutical industry-supported (Wyeth, Eli Lily, Servier, Pfizer, AstraZeneca) projects focused on the identification and better management of anxiety and depression. He has led investigator initiated studies into the antidepressant and linked circadian impacts of agomelatine. These studies have been supported by Servier, the manufacturer of agomelatine. He is the Chief Scientific Advisor to, and an equity shareholder in, InnoWell. InnoWell has been formed by the University of Sydney and PwC to pursue the transformation of mental health services through the use of innovative technologies. All other authors declare no conflicts of interest.
Funding Statement
Data collection for AGDS was possible thanks to funding from the Australian National Health & Medical Research Council (NHMRC) to NGM, NRW, SEM, IHB, EMB, PAL (GNT1086683) and Medical Research Future Fund (APP1200644). We thank our colleagues Richard Parker, Simone Cross, Scott Gordon and Lenore Sullivan for their valuable work coordinating all the administrative and operational aspects of the AGDS project. NRW thanks the support of NHMRC through grants 1113400 and 1173790. MER thanks the support of NHMRC and the Australian Research Council (ARC) through an NHMRC-ARC Dementia Research Development Fellowship (GNT1102821). SEM is supported in part by NHMRC investigator grant APP1172917. The views expressed are those of the authors and not necessarily those of the affiliated or funding institutions.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The QIMR Berghofer Medical Research Institute Human Research Ethics Committee approved all questionnaires and research procedures for the AGDS under project number P2118
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Summary data on effects described in this manuscript is available in the results section. GWAS summary statistics used in this study are publicly available and have been disclosed in the methods but are also available upon request. Code related to this study data analysis is available upon request from the authors. Access to the AGDS individual level data is restricted due to the ethical guidelines governing the study.
